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Theaimofthisstudywastodeterminetheclinicalsigniﬁcancesofp53andp-glycoprotein(P-gp)expressiononoutcomepredictors
for patients with DLBC. We assessed the immunohistochemical expression of p53 and P-gp using formalin-ﬁxed, paraﬃn-
embedded specimens in 108 patients diagnosed with de novo DLBC. A high expression of p53 was found in 53.7% of the patients.
No expression of P-gp was demonstrated in any of the specimens. There were no signiﬁcant diﬀerences in the complete remission
(CR) rate (P = 0.79), overall survival (OS) (P = 0.73), or disease-free survival (DFS) (P = 31) between the p53-positive and p53-
negative groups. The ﬁnal model from multivariate analysis that revealed poor performance status was signiﬁcantly associated
with CR (P<0.001) and OS (P<0.001). Moreover, the advanced stage was a signiﬁcant predictor of DFS (P = 0.03). This study
demonstrated no impact of the expression of p53 on either response or survival rates.
1.Introduction
Diﬀuse large B-cell lymphoma (DLBC) is the most common
type of non-Hodgkin lymphoma (NHL) accounting for 50%
ofNHLinThailand[1].Althoughtheoutcomesoftreatment
were markedly improved by adding rituximab to standard
CHOPregimen(R-CHOP)[2],the5-yearevent-freesurvival
rate was only 47% [3]. Stratifying newly diagnosed patients
according to risk will provide invaluable information to
achieve the optimal risk-adapted strategy. Since the Inter-
national Prognostic Index (IPI) was introduced in 1993,
the strong prognostic predictability has been proved [4, 5].
However, patients with high-risk IPI may be unsuitable for
intensive therapy due to old age or poor performance status
(PS). Therefore, additional prognostic factors reﬂecting
tumor biology are needed to identify patients who might
beneﬁt from dose intensiﬁcation or new targeted therapy.
The p53 tumor suppressor gene is located on the short
arm of chromosome 17 (17p13.1). It plays a role in the
regulation of cell survival acting as a cell-cycle checkpoint
protein and apoptotic cell death. Therefore, the p53 protein
contributes to preventing the replication of cells suﬀering
from DNA damage. Loss of the p53 function may cause
resistance to apoptosis that leads to treatment failure to
DNA-damaging agents [6]. Thus, p53 inactivation may be
associated with a poorer prognosis. However, it remains
inconclusive whether the p53 expression is an independent
outcome predictor in patients with non-Hodgkin lymphoma
(NHL) [7].
In addition, another major reason for treatment failure is
drug resistance. Several biological mechanisms are responsi-
ble for this problem. One of the most important reasons that
has been extensively investigated is the multidrug resistance
(MDR) gene. The classical MDR is related to the expression
of the MDR-1 gene, which is located at chromosome 7
andencodesa170-kDamembrane-associatedP-glycoprotein
(P-gp) [8]. The P-gp functions as an energy-dependent
drug eﬄux pump and causes a reduction in intracellular2 ISRN Oncology
accumulation of the drug. In NHL, varying incidences of P-
gp expression were reported from 0 to 49% and its impacts
on the response are controversial [9–11].
In this study, we evaluated p53 and P-gp expression,
as well as clinical parameters in patients with DLBC. The
purpose was therefore to verify their impacts on treatment
outcomes.
2.MaterialsandMethods
From January 2003 to December 2006, 122 patients were
enrolled at Songklanagarind Hospital, but only 108 patients
had available tissue sections. The eligibility criteria were
older than 18 years, newly diagnosed with DLBC, and had
stage II–IV diseases. The patients with human immun-
odeﬁciency virus or primary extranodal lymphomas were
excluded. For lymphoma immunophenotyping, monoclonal
antibodies targeting CD3, CD5, CD20, and CD79a (Dako,
Glostrup, Denmark) were used to determine the T- or B-cell
lineage. This study was approved by the Ethics Committee of
Prince of Songkla University.
Clinical stage was performed using the Ann Arbor stag-
ing system. All patients with stage II–IV were treated with a
standard chemotherapy of cyclophosphamide, doxorubicin,
vincristine, and prednisolone (CHOP) for at least six cycles.
Rituximab was not routinely administered in Thailand. After
completion of treatment, all patients were regularly followed
up at intervals every few months for at least 5 years or until
death.
2.1.ImmunohistochemicalStaining. Tumor samples were ob-
tained by tissue biopsy at the time of initial diagnosis.
Eighteen samples at the time of relapse for additional P-gp
study were also included. The expressions of p53 and P-gp
were analyzed by immunohistochemistry using the Envision
technique. The immunohistochemistry was performed in
formalin-ﬁxed paraﬃn-embedded tissue sections. The 5-
µm-thick sections were cut on aminopropyltriethoxysilane-
coated slides. They were deparaﬃnized in xylene and
rehydrated through graded alcohol. Antigen retrieval was
carried out by high-temperature and- pressure cooking in
Tris EDTA pH 9 for 30 seconds. After rinsing in distilled
water, the endogenous peroxidase activity was blocked by
treating the slides with 3% hydrogen peroxide for 5 minutes.
To inhibit nonspeciﬁc antibody binding, the tissue samples
were reacted with nonimmune serum for half an hour in a
moisture chamber. The sections were incubated overnight
at 4◦C with 1:250 and 1:40 dilutions of the monoclonal
antibody of p53 (DO-7, DAKO, Glostrup, Denmark) and P-
gp (Novocastra Laboratories, UK), respectively. After rinsing
in phosphate-buﬀered saline solution, the sections were
incubated with Envision for 30min and then were rinsed
in phosphate-buﬀered saline solution again. The color was
developedusingdiaminobenzidine (DAB)solutionfor5min
and counterstained with hematoxylin. Any brown nuclear
and membrane staining of the tumor cells were taken as
positive for p53 and P-gp, respectively.
2.2. Immunohistological Scoring. The scoring was analyzed
in the area of highest protein expression scanning under
low magniﬁcation (×100). Then, at least 500 cells under
high-power ﬁeld (×1000) were evaluated for a ﬁnal score.
Negative staining was made after carefully examining the
entire section with high magniﬁcation. Expression of p53
and P-gp was semiquantitatively assessed without knowledge
of the clinical outcome. The staining was graded on a scale
of 1+, 2+, and 3+ when 10–24%, 25–49%, and 50% positive
r e a c t i o n sw e r ef o u n d ,r e s p e c t i v e l y[ 12]. Paraﬃn-embedded
placentawasusedasapositive controlforP-gp(Figure 1(c)).
2.3. Statistical Analysis. Baseline categorical characteristics
were compared among patients with and without overex-
pression of p53 using Chi-square. Logistic regression model
was used to predict complete remission (CR). Univariate
analysis of survival was performed with the Kaplan-Meier
method. Overall survival (OS) was calculated as the time
interval from the date of diagnosis to death or last follow-up.
Disease-free survival (DFS) was deﬁned as the time interval
between CR and ﬁrst progression/relapse or death from any
cause. Kaplan-Meier methods were used to estimate time-
to-event endpoints, including OS and DFS. Survival data
between subgroups were compared using the log-rank test.
Multivariate analyses for OS and DFS were performed using
a Cox regression model with backward elimination. Critical
P-values for entry and removal were 0.2 and 0.5, respectively.
To test the main hypothesis, we forced the p53 into the
model. Hazard ratios (HRs), 95% conﬁdence intervals (95%
CI) and P-values were obtained from the best-ﬁt model. All
the statistic analyses were calculated using the R program. A
signiﬁcance level of 0.05 was used throughout all statistical
tests in the study.
3. Results
There were 122 DLBC patients diagnosed during the study
period. However, only 108 patients with adequate paraﬃn-
embedded tumor tissue sections were analyzed. To avoid
bias, we compared the clinical characteristics and outcomes
between the 108 and 14 patients and found no statistically
signiﬁcantdiﬀerences(datanotshown).Therewere56males
and 52 females with a median age of 53.8 years (range
18–84 years). The majority of patients were treated with
CHOP chemotherapy. Rituximab was administered in eight
patients (7.4%). The median OS and DFS were 27.9 months
(range 1–68 months) and 30.9 months (range 0–74 months),
respectively with a median follow-up time of 19.7 months
(range 0.3–66.2 months).
3.1. Expression of p53 and P-gp. Assessment of p53 expres-
sion was performed in 108 patients. Of these, 30 (27.8%)
were p53− (Figure 1(a)), 5 (4.6%) were p53+, 15 (13.9%)
were p53++ (Figure 1(b)), and 58 (53.7%) were p53+++
(Figure 1(a)). A comparison between clinical characteristics
andp53overexpressionshowednosigniﬁcancesinanyofthe
variables (Table 1).ISRN Oncology 3
(a) (b)
(c) (d)
Figure 1: Immunohistochemical detection showing (×400) (a) negative for p53 staining in DLBC, (b) strongly positive for p53 staining in
DLBC (+++), (c) placenta as a positive control for P-gp staining, (d) negative for P-gp staining in DLBC.
All tissue sections from patients with newly diagnosed
and relapsed DLBC were negative for P-gp expression
(Figure 1(d)).
3.2. Univariate Analysis. Patients with bulky mass, poorer
performance status (PS), and higher IPI were less likely to
achieve CR. The results from univariate analysis showed
that those who presented with at least one of the variables
(more advanced stage, B symptoms, bulky mass, high
LDH, poorer performance status, and/or higher IPI) were
signiﬁcantly associated with a shorter overall survival (OS).
Simultaneously, only stage, B symptom, LDH, and IPI were
signiﬁcantly associated with the DFS (Table 2). There were
no signiﬁcant diﬀerences in the CR rate (P = 0.79), OS
(P = 0.73), or DFS (P = 31) between the p53-positive (3+)
and p53-negative groups (0–2+), even we tried to change the
cut-oﬀ values to 1+ or 2+ (data not shown).
3.3.MultivariateAnalysis. Thepreliminaryregressionmodel
included the following variables: p53, sex, age group, stage,
B symptoms, bulky mass, extranodal involvement, LDH and
performance status. The ﬁnal model revealed PS 2–4 was
signiﬁcantly associated with lower CR rate (OR 14.7, 95% CI
4.8–45.3, P<0.001) and shorter OS (HR 5, 95% CI 2.8–9,
P<0.001). Moreover, the advanced stage was a signiﬁcant
predictor of DFS (P = 0.03). Patients with stage III had HR
3.1 (95% CI 1.3–7.5) while patients with stage IV had HR 2.7
(95% CI 1.1–7.1).
4. Discussion
This study was undertaken to investigate the impact of
p53 and P-gp expression as well as clinical parameters on
treatment outcomes in patients with de novo DLBC. From
multivariate analysis, our results indicate that only poor PS
was independently associated with both CR and OS while
the advanced stage was the independent predictor of DFS.
Contrary to our expectations, the expression of p53 shows
no impact on either response or survival rates. Furthermore,
both initial and relapsed specimens were negative for P-gp
expression.4 ISRN Oncology
Table 1:Clinicalcharacteristicsofthe108patientsaccordingtop53
expression.
Variables
Immunostaining for p53 (no.)
P-value
0–2+ 3+
Age group 0.69
≤60 years 20 47
>60 years 10 31
Sex 0.68
Male 17 39
Female 13 39
Bs y m p t o m s 0 . 6 7
Absent 16 47
Present 14 31
Bulky mass (>6cm) 0.39
Absent 25 57
Present 5 21
Extranodal involvement 0.86
Absent 11 29
Present 19 49
Serum LDH level 0.90
Normal 13 31
High 17 47
Ann Arbor staging
system 0.12
II 11 37
III 12 16
IV 7 25
ECOG performance
status 0.46
0-1 25 58
2–4 5 20
International prognostic
index 0.85
Low 8 15
Low intermediate 15 28
High intermediate 8 21
High 5 14
Although there have been several studies on these mark-
ers, conﬂicting results have still existed. Moreover, indepen-
dentassociationsbetweentheindividualmarkersandknown
clinical prognostic factors were not assessed. To address this,
the relationship of the p53 expression with clinical endpoints
was independently determined with clinical characteristics.
We included only patients who were ethnic Thais and
diagnosed with DLBC subtype to avoid confounding eﬀects.
In addition, they were homogeneously treated with the
same anthracycline-containing regimen, and the treatment
outcomes were analyzed based on complete follow-up data.
In our study, no expression of P-gp in any of the spec-
imens was demonstrated. We tested three possible explana-
tions to conﬁrm the negative immunohistochemical results.
First, we tried diﬀerent concentrations of the P-gp antibody.
Table 2: Univariate analysis of CR, OS and DFS for 107 patients
treated at Songklanagarind hospital.
Variables Total
Univariate analysis
CR no. (%) OS HR (95%
CI)
DFS HR
(95% CI)
Age group, y
≤60 45 (68.2) 1.0 1.0
>60 26 (63.4) 1.4 (0.9–2.4) 1.2 (0.6–2.5)
Sex
Male 39 (70.9) 1.0 1.0
Female 32 (61.5) 1.1 (0.6–1.8) 0.9 (0.4–1.8)
Stage
II 35 (72.9) 1.0 1.0
III 18 (64.3) 2.0 (1.1–3.7) 3.2 (1.3–7.7)
IV 18 (58.1) 2.1 (1.1–3.9)∗ 2.5
(1.0–6.3)∗
Bs y m p t o m s
Absent 45 (72.6) 1.0 1.0
Present 26 (57.8) 1.9 (1.1–3.1)∗ 2.6
(1.2–5.4)∗
Bulky mass
Absent 59 (72.0) 1.0 1.0
Present 12 (48.0)∗ 2.0 (1.1–3.6)∗ 0.5 (0.1–1.9)
Extranodal
Absent 30 (75.0) 1.0 1.0
Present 41 (61.2) 1.5 (0.9–2.7) 1.4 (0.7–3.0)
LDH
Normal 34 (77.3) 1.0 1.0
High 37 (58.7) 1.9 (1.1–3.3)∗ 2.4
(1.1–5.2)∗
PS
0-1 66 (79.5) 1.0 1.0
2–4 5 (20.8)∗∗ 4.8 (2.7–8.3)∗∗ 1.5 (0.4–4.8)
p53
0–(2+) 36 (72) 1.0 1.0
3+ 35 (61.4) 1.2 (0.7–2.0) 0.9 (0.4–1.9)
IPI
Low 20 (87.0) 1.0 1.0
Low Int. 29 (78.4) 1.5 (0.6–3.4) 1.2 (0.4–3.6)
High Int. 16 (57.1) 3.6 (1.6–8.2) 3.3 (1.1–9.7)
High 6 (31.6)∗∗ 5.3 (2.2–12.6)∗∗ 3.4
(0.9–13.0)∗
∗P<. 05, ∗∗P<. 001.
Second, a few specimens with faint staining were repeated
using an automatic immunostaining device (DAKO). These
two hypotheses about the methods are unlikely to be
responsible in the negative staining due to that the paraﬃn-
embedded placenta showed positive staining. Another rea-
sonable assumption is that the sample size was too small to
detect the low positive expression rate of P-gp (95% conﬁ-
denceinterval=0–3.4%and0–18.5%inthenewlydiagnosed
andrelapsedpatients,respectively).Basedonourknowledge,ISRN Oncology 5
the negative result of P-gp from the immunohistochemical
method has never been reported. One explanation may be
from publication bias. Though the evidence shows that both
RT-PCR and immunohistochemistry are reliable methods
to detect MDR expression in lymphomas [10], the fresh
specimens were not obtained to assess the expression of
MDR-1 mRNA and P-gp that could strongly conﬁrm the
negative expression in this study.
Based on a cut-oﬀ value greater than 50% of positive
immunostaining for p53, the positive rate of 53.7% is
consistent with a report from Italy [13]. In addition, Chang
et al. [14] demonstrated 58% of patients with high clinical
stage DLBC stained positive for p53 using the cut-oﬀ value
of 20% as a positive expression. Paik et al. [15] also showed
overexpression of p53 in 56% of nodal DLBC with germinal
centre phenotype based on nuclear staining more than 10%.
However, our positive rate is higher than a population-based
study using the cut-oﬀ value of 50% that shows that only
13% of 364 cases with B-cell lymphomas were positive [16].
Regarding the prognostic signiﬁcance of p53, no signiﬁcant
relationship between p53 protein expression and any of the
clinical variables and outcomes was conﬁrmed in this study.
These results were in concordance with a population-based
study [16]. Similarly, nothing signiﬁcant in survival was
observed in previous studies [17, 18]. On the other hand,
our results contradicted to the study that demonstrated the
impact of p53 on survival [19, 20].
Altogether, this study provides evidence that both of
the well-known biomarkers, p53 and P-gp, are not the
independent predictors for treatment outcomes in these
patients with DLBC. Nowadays, gene expression signatures
provide evidences to predict the prognosis in patients with
DLBC [21, 22]. Nevertheless, given the limitations of routine
clinical utility, gene expression proﬁling in daily practice has
allowed the immunohistochemistry to be of great practical
value.
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